Highest-materiality recent filing
Contineum reports Q1 net loss $14.5M; cash $246.3M through mid-2029
Cash, cash equivalents and marketable securities of $246.3M as of March 31, 2026; runway through mid-2029.
Contineum PIPE-791 Phase 1b shows safety, numeric pain reduction vs placebo
43-patient crossover trial met primary safety endpoint; no serious AEs, most common TEAEs: headache (n=3), fatigue (n=2).
Contineum reports Q4 2025 net loss of $15.2M; upsizes ATM to $100M; Phase 2 IPF trial dosed
Net loss of $15.2M vs $14.6M in Q4 2024; R&D expenses $12.8M, G&A $4.4M.
Contineum Therapeutics approves 2026 Inducement Plan with 750,000 share reserve
Board approved 2026 Employment Inducement Equity Incentive Plan on January 23, 2026.
Contineum prices upsized $90M public offering at $12.25/share; net proceeds ~$84.2M
7,346,938 shares of Class A common stock sold at $12.25 per share, up from planned $75M.
Contineum Therapeutics starts Phase 2 trial of PIPE-791 for IPF; 324 subjects, completion June 2028
Submitted Phase 2 trial details for PIPE-791 to ClinicalTrials.gov; expects ~324 IPF patients enrolled globally.
Contineum's PIPE-307 Phase 2 RRMS trial misses primary endpoint
Phase 2 VISTA trial of M1 receptor antagonist PIPE-307 did not meet primary or secondary efficacy endpoints.
Contineum Therapeutics Q3 net loss $12.8M, cash $182.4M, pipeline milestones affirmed
Cash, cash equivalents and marketable securities $182.4M; projected cash runway extended through 2028.
Contineum reports positive Phase 1b PET data for PIPE-791; confirms target engagement
PIPE-791 achieved high LPA1 brain receptor occupancy in healthy volunteers and PrMS patients.
Contineum Q2 net loss $16M, cash $175.5M; PIPE-307 VISTA top line data Q4 2025
Net loss of $16.0M for Q2 2025 vs $9.0M in Q2 2024; R&D expenses $14.1M (+78% YoY).
Contineum Therapeutics elects three Class I directors, ratifies EY as auditor at 2025 annual meeting
Sarah Boyce elected with 12.7M votes for vs. 641.9K withheld; broker non-votes 2.05M.
Contineum Q1 net loss $16.0M, cash $190.7M; files $300M shelf & $75M ATM
Net loss of $16.0M vs $8.4M in Q1 2024; R&D expenses rose 76% to $13.7M.
Contineum Therapeutics appoints Timothy Watkins as CMO and Head of Development
Dr. Watkins appointed Chief Medical Officer effective April 28, 2025, succeeding Dr. Stephen Huhn.
Contineum appoints Diego Miralles, M.D. to board of directors
Dr. Miralles appointed as Class II director effective March 14, 2025, term expiring at 2026 annual meeting.
Contineum reports Q4 2024 net loss of $14.6M, cash $204.8M, runway through 2027
Net loss $14.6M in Q4 2024 vs $7.8M in Q4 2023; R&D expenses $13M (+62% YoY).
Contineum reports Q3 2024 cash $213.9M, VISTA trial enrollment on track
Cash, equivalents and marketable securities $213.9M as of Sept 30, 2024 (vs $125.2M at end of 2023).
Contineum Q2 cash $218.7M; R&D $7.9M; IPO net $107.9M; Phase 2 enrollment on track
Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at YE 2023.
Contineum Q2 cash $218.7M; PIPE-307 Phase 2 enrollment on track
Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at year-end 2023.
Contineum Therapeutics appoints Sarah Boyce to Board, effective June 24, 2024
Sarah Boyce appointed as Class I director and Chair of Nominating and Corporate Governance Committee.
Contineum Therapeutics adopts Executive Severance Plan for named executive officers
CEO Carmine Stengone designated Tier 1 participant; CSO Lorrain, CFO Slover designated Tier 2 participants.
Contineum Therapeutics appoints Troy Ignelzi to board as Audit Committee Chair
Troy Ignelzi appointed as Class I director and Chair of Audit Committee, effective May 20, 2024.
Contineum Q1 2024 cash $117.9M; IPO net proceeds $108M extend runway to 2027
Cash and securities $117.9M at March 31; proforma cash (incl. IPO) $225.9M.
Contineum Therapeutics adopts amended charter and bylaws upon IPO closing
Authorized 200M Class A common and 20M Class B common shares, plus 10M undesignated preferred.
On March 14, 2025, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Diego Miralles, M.D. as a member of its Board, effective March 14, 2025.
On June 21, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Sarah Boyce as a member of its Board, effective June 24, 2024.
On May 20, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Troy Ignelzi as a member of its Board, effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event other_material